ATE511855T1 - Adjuvansformulierung zur scheimhaut-applikation - Google Patents

Adjuvansformulierung zur scheimhaut-applikation

Info

Publication number
ATE511855T1
ATE511855T1 AT01912024T AT01912024T ATE511855T1 AT E511855 T1 ATE511855 T1 AT E511855T1 AT 01912024 T AT01912024 T AT 01912024T AT 01912024 T AT01912024 T AT 01912024T AT E511855 T1 ATE511855 T1 AT E511855T1
Authority
AT
Austria
Prior art keywords
pumular
application
adjuvant formulation
adjuvant
mucosal
Prior art date
Application number
AT01912024T
Other languages
English (en)
Inventor
Jan Raa
Aud K H Berstad
Hilde Bakke
Bjorn Haneberg
Inger Lise Haugen
Johan Holst
Liba Janakova
Gro E Korsvold
Fredrik Oftung
Original Assignee
Biotec Pharmacon Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotec Pharmacon Asa filed Critical Biotec Pharmacon Asa
Application granted granted Critical
Publication of ATE511855T1 publication Critical patent/ATE511855T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01912024T 2000-02-23 2001-02-02 Adjuvansformulierung zur scheimhaut-applikation ATE511855T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/511,582 US20020009463A1 (en) 2000-02-23 2000-02-23 Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
PCT/IB2001/000144 WO2001062283A2 (en) 2000-02-23 2001-02-02 Mucosal adjuvant formulation

Publications (1)

Publication Number Publication Date
ATE511855T1 true ATE511855T1 (de) 2011-06-15

Family

ID=24035524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01912024T ATE511855T1 (de) 2000-02-23 2001-02-02 Adjuvansformulierung zur scheimhaut-applikation

Country Status (10)

Country Link
US (3) US20020009463A1 (de)
EP (1) EP1259259B1 (de)
JP (2) JP4947506B2 (de)
CN (1) CN1404399B (de)
AT (1) ATE511855T1 (de)
AU (1) AU771205B2 (de)
DK (1) DK1259259T3 (de)
ES (1) ES2369550T3 (de)
NO (1) NO331017B1 (de)
WO (1) WO2001062283A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JPWO2003039567A1 (ja) * 2001-11-06 2005-02-24 株式会社オリエントキャンサーセラピー 抗癌組成物
CN1607941A (zh) * 2001-11-19 2005-04-20 贝克顿迪肯森公司 粒状药物组合物
EP1506007B1 (de) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Kombinationsimpfstoff gegen bakterielle meningitis, der über die schleimhaut appliziert wird
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US11783925B2 (en) 2006-12-29 2023-10-10 Kip Prod P1 Lp Multi-services application gateway and system employing the same
US20170344703A1 (en) 2006-12-29 2017-11-30 Kip Prod P1 Lp Multi-services application gateway and system employing the same
US9569587B2 (en) 2006-12-29 2017-02-14 Kip Prod Pi Lp Multi-services application gateway and system employing the same
US11316688B2 (en) 2006-12-29 2022-04-26 Kip Prod P1 Lp Multi-services application gateway and system employing the same
US8280978B2 (en) 2006-12-29 2012-10-02 Prodea Systems, Inc. Demarcation between service provider and user in multi-services gateway device at user premises
US9602880B2 (en) 2006-12-29 2017-03-21 Kip Prod P1 Lp Display inserts, overlays, and graphical user interfaces for multimedia systems
CN101244267B (zh) * 2007-02-12 2011-12-21 复旦大学 一种增强微生物疫苗免疫原性的免疫制剂
WO2008102151A1 (en) * 2007-02-21 2008-08-28 Biotec Pharmacon Asa Medical uses of glucans
JP5272129B2 (ja) * 2007-04-25 2013-08-28 幸仁 秋山 インフルエンザウイルスの不活化抗原に対するアジュバント、及び分泌型ＩｇＡ抗体誘導剤
TWI496578B (zh) * 2009-10-08 2015-08-21 Aureo Co Ltd 流感病毒感染症的治療劑
US20130079299A1 (en) * 2010-05-12 2013-03-28 Glucan Corporation Arthritis Therapeutic Agent
WO2012014978A1 (ja) * 2010-07-29 2012-02-02 国立大学法人北海道大学 免疫アジュバント
EP2694030A2 (de) 2011-03-04 2014-02-12 Sana Pharma AS Kosmetische formulierungen
EP2825106B1 (de) 2012-03-13 2019-05-08 Becton Dickinson France Injektionsvorrichtung mit einem miniaturisierten arzneimittelabgabeteil
CA3097980A1 (en) * 2018-04-24 2019-10-31 Memorial Sloan Kettering Cancer Center Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
CN111420044B (zh) * 2020-05-11 2021-04-09 中逸安科生物技术股份有限公司 一种四价流感病毒亚单位疫苗及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071750D1 (en) * 1979-07-04 1986-10-16 Kureha Chemical Ind Co Ltd Nasal preparations, process for making same and their use
DE3019614A1 (de) * 1980-05-22 1981-12-03 Sankyo Co., Ltd., Tokyo Hydrolysiertes polysaccharid
EP0045718A3 (de) * 1980-07-25 1983-01-19 Ciba-Geigy Ag Nasalpräparate und Verfahren zu deren Herstellung
US4857318A (en) * 1983-11-07 1989-08-15 Syntex (U.S.A.) Inc. Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP1089751A4 (de) * 1998-06-23 2001-07-25 Univ Leland Stanford Junior Adjuvante therapie

Also Published As

Publication number Publication date
DK1259259T3 (da) 2011-08-01
NO331017B1 (no) 2011-09-12
NO20023935D0 (no) 2002-08-19
JP2003523401A (ja) 2003-08-05
EP1259259B1 (de) 2011-06-08
ES2369550T3 (es) 2011-12-01
NO20023935L (no) 2002-10-15
US20120014991A1 (en) 2012-01-19
WO2001062283A3 (en) 2002-02-14
WO2001062283A2 (en) 2001-08-30
EP1259259A2 (de) 2002-11-27
AU771205B2 (en) 2004-03-18
US20030104010A1 (en) 2003-06-05
US20020009463A1 (en) 2002-01-24
CN1404399B (zh) 2012-04-04
AU4094301A (en) 2001-09-03
JP4947506B2 (ja) 2012-06-06
CN1404399A (zh) 2003-03-19
JP2011190278A (ja) 2011-09-29

Similar Documents

Publication Publication Date Title
ATE511855T1 (de) Adjuvansformulierung zur scheimhaut-applikation
AU3847801A (en) Proteosome influenza vaccine
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
DK1404363T3 (da) Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
HUP0301180A2 (hu) Imidazokinolinaminok adjuvánsként való használata DNS vakcinálásban
EP1594536A4 (de) Adjuvante influenza-vakzine
WO2004030608A3 (en) Nanoemulsion vaccines
ATE542829T1 (de) Impfstoff
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
UY26882A1 (es) Nuevo tratamiento
ATE274919T1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
WO2003093298A3 (en) Immunogenic peptides
WO2002032455A3 (en) Vaccine
EE200300172A (et) Antigeenne kompositsioon ja adjuvantsegu
GB0703976D0 (en) Liposome preparation
AU2003294191A8 (en) Inclusion bodies for the oral vaccination of animals
GB0409559D0 (en) Polypeptide
AR027540A1 (es) Utilizacion de la proteina mic3 de toxoplasma gondii o de uno de sus derivados como agente inmunogeno o como antigeno de vacunacion
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties